Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: KalVista Pharmaceuticals, Inc.

Market Cap 1.44B 1.25B 1.15B 1.08B 2.01B 138B 2.06B 13.72B 5.31B 66.35B 5.4B 5.28B 231B P/E Ratio 2026 *
-30.8x
P/E Ratio 2027 * 17.5x
Enterprise Value 1.3B 1.12B 1.04B 972M 1.82B 124B 1.85B 12.37B 4.79B 59.83B 4.87B 4.76B 208B EV / Sales 2026 *
6.21x
EV / Sales 2027 * 3.51x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 day+0.04%
1 week+0.19%
Current month+0.48%
1 month+1.01%
3 months+46.42%
6 months+60.14%
Current year+67.18%
1 week 26.94
Extreme 26.94
27
1 month 26.68
Extreme 26.68
27
Current year 14.22
Extreme 14.22
27
1 year 9.83
Extreme 9.83
27
3 years 7.21
Extreme 7.21
27
5 years 4.12
Extreme 4.12
30.7
10 years 0
Extreme 0
45
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 2016-10-31
Chief Executive Officer 61 2024-03-05
Director of Finance/CFO 51 2024-09-08
Director TitleAgeSince
Director/Board Member 61 2024-03-05
Director/Board Member 76 2014-11-30
Chairman 67 2022-10-12
Date Insider Type Main position Quantity % Market Cap.
05-26Fiscal year

Executive/Senior Manager

101,400 0.2006%
05-25Sell

Chief Technology Officer

-2,239 0.0044%
05-25Sell

Executive/Senior Manager

-1,489 0.0029%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%+0.19%+90.01%+172.45% 1.44B
+1.65%+6.42%+53.16%+109.62% 54.82B
+0.03%-1.80%+49.57%+43.94% 43.27B
+3.81%-0.98%-15.88%-19.20% 21.79B
+5.99%-7.18%-0.60%+399.44% 19.92B
+0.81%-8.38%+12.77%-33.24% 15.67B
+0.53%+2.08%+8.89%-40.13% 15.26B
+2.29%+2.43%+29.77%+181.64% 13.22B
-5.27%+3.89%+90.88%+208.02% 11.58B
-1.74%-1.05%+12.88% - 11.94B
Average +0.82%-0.50%+33.14%+113.62% 20.89B
Weighted average by Cap. +1.27%+1.15%+32.39%+98.35%

Financials

2026 *2027 *
Net sales 209M 181M 167M 156M 292M 19.98B 298M 1.99B 771M 9.63B 783M 767M 33.49B 348M 302M 279M 261M 488M 33.36B 498M 3.32B 1.29B 16.08B 1.31B 1.28B 55.91B
Net income -68.56M -59.49M -54.84M -51.38M -96.01M -6.56B -98.01M -654M -253M -3.16B -257M -252M -11B 44.07M 38.25M 35.26M 33.03M 61.72M 4.22B 63.01M 421M 163M 2.03B 165M 162M 7.07B
Net Debt -141M -123M -113M -106M -198M -13.53B -202M -1.35B -522M -6.52B -530M -519M -22.68B -216M -188M -173M -162M -303M -20.71B -309M -2.06B -799M -9.98B -812M -794M -34.71B
Logo KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
Employees
275
Date Price Change Volume
26-06-10 27.00 $ +0.04% 4,272,770
26-06-09 26.99 $ 0.00% 1,537,918
26-06-08 26.99 $ +0.15% 1,872,646
26-06-05 26.95 $ 0.00% 1,834,288
26-06-04 26.95 $ 0.00% 826,065
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
27.00USD
Average target price
28.60USD
Spread / Average Target
+5.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KALV Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!